Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Futura Medical passes major milestone as it doses first patient in phase III study

MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis
couple in bed
An earlier phase II assessment of Futura’s glyceryl trinitrate proved its efficacy, safety and a rapid speed of onset

Futura Medical PLC (LON:FUM) said it has dosed the first patient in its phase III clinical study of MED2002, a gel used to treat erectile dysfunction.

Headline data from the trial is expected next year. MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis. It works without side-effects such as headaches.

WATCH: Futura Medical doses first patient in phase III study

An earlier phase II assessment of Futura’s glyceryl trinitrate proved its efficacy, safety and a rapid speed of onset.

Randomised study

The current study is a randomised, double-blind and placebo-controlled, which means half the trial group receive a substance with no therapeutic value.

Only at the end of the assessment will researchers know which cohort received the active gel.

Different doses of MED2002 will be used to find the optimum application.

Chief executive James Barder said the enrolment of the first person to the phase III study was a “major milestone”.

"Futura is now in a position to build value by progressing the development of MED2002 through its planned phase III studies, and we are excited to be moving closer to bringing an innovative, highly differentiated ED [erectile dysfunction] product to market that could help the many ED patients whose needs are not met by current treatments."

 

View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use